Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria

Clinical Science

Volumn 114, Issue 5-6, 2008, Pages 449-455

  Ferroni, Patrizia ^a   Guagnano, Maria Teresa ^b   Falco, Angela ^b   Paoletti, Vincenzo ^c   Manigrasso, Maria Rosaria ^b   Michetti, Noemi ^b   Santilli, Francesca ^b   Guadagni, Fiorella ^a   Basili, Stefania ^c   Davì, Giovanni ^b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Hypertension; Inflammation; Microalbuminuria; Platelet activation; Soluble CD40 ligand (sCD40l); Thrombosis

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; N(G),N(G) DIMETHYLARGININE; PADGEM PROTEIN; VON WILLEBRAND FACTOR; LIPID;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FEMALE; GENDER; HUMAN; HYPERTENSION; INFLAMMATION; MALE; MICROALBUMINURIA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; THROMBOCYTE ACTIVATION; ALBUMINURIA; BLOOD; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

AGED; AGED, 80 AND OVER; ALBUMINURIA; C-REACTIVE PROTEIN; CD40 LIGAND; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; VON WILLEBRAND FACTOR;

EID: 40649106517     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20070307     Document Type: Article

References (43)

1. Mach, F., Schonbeck, U., Sukhova, G. K. et al. (1997) Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implication for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 94, 1931-1936
2. van Kooten, C. (2000) Immune regulation by CD40-CD40L interactions. Front. Biosci. 5, 680-693
3. Henn, V., Slupsky, J. R., Grafe, M. et al. (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391, 591-594
4. Aukrust, P., Muller, F., Ueland, T. et al. (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100, 614-620
5. Lindmark, E., Tenno, T. and Siegbahn, A. (2000) Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler. Thromb. Vasc. Biol. 20, 2322-2328
6. Granger, D. N., Vowinkel, T. and Petnehazy, T. (2004) Modulation of the inflammatory response in cardiovascular disease. Hypertension 43, 924-931
7. Prasad, K. S., Andre, P., Yan, Y. and Phillips, D. R. (2003) The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr. Opin. Hematol. 10, 356-361
8. Freedman, J. E. (2003) CD40-CD40L and platelet function. Beyond hemostasis. Circ. Res. 92, 944-946
9. Cipollone, F., Mezzetti, A., Porreca, E. et al. (2002) Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 106, 399-402
10. Garlichs, C. D., Kozina, S., Fateh-Moghadam, S. et al. (2003) Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 34, 1412-1418
11. Danese, S., Katz, J. A., Saibeni, S. et al. (2003) Activated filatelets are the source of elevated levels of soluble CD40 igand in the circulation of inflammatory bowel disease patients. Gut 52, 1435-1441
12. Lim, H. S., Blann, A. D. and Lip, G. Y. (2004) Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 109, 2524-2528
13. Falco, A., Romano, M., Iapichino, L., Collura, M. and Davi, G. (2004) Increased soluble CD40 ligand levels in cystic fibrosis. J. Thromb. Haemostasis 2, 557-560
14. Roselli, M., Mineo, T. C., Basili, S. et al. (2004) Soluble CD40 ligand plasma levels in lung cancer. Clin. Cancer Res. 10, 610-614
15. Novo, S., Basili, S., Tantillo, R. et al. (2005) Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke 36, 673-675
16. Schonbeck, U., Varo, N., Libby, P., Buring, J. and Ridker, P. M. (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104, 2266-2268
17. Mo, V. Y. and De Lemos, J. A. (2004) Individualizing therapy in acute coronary syndromes: using a multiple biomarker approach for diagnosis, risk stratification, and guidance of therapy. Curr. Cardiol. Rep. 6, 273-278
18. Davi, G., Gresele, P., Violi, F. et al. (1997) Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 96, 69-75
19. Spencer, C. G., Gurney, D., Blann, A. D., Beevers, D. G. and Lip, G. Y. (2002) Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 40, 61-66
20. Minuz, P., Patrignani, P., Gaino, S. et al. (2004) Determinants of platelet activation in human essential hypertension. Hypertension 43, 64-70
21. Nadar, S. K., Blann, A. D., Kamath, S., Beevers, D. G. and Lip, G. Y. H. (2004) Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J. Am. Coll. Cardiol. 44, 415-422
22. Blann, A. D., Nadar, S. and Lip, G. Y. (2003) Pharmacological modulation of platelet function in hypertension. Hypertension 42, 1-7
23. Sesso, H. D., Buring, J. E., Rifai, N., Blake, G. J., Gaziano, J. M. and Ridker, P. M. (2003) C-reactive protein and the risk of developing hypertension. JAMA, J. Am. Med. Assoc. 290, 2945-2951
24. Pedrinelli, R., Dell'Omo, G., Di Bello, V. et al. (2004) Low-grade inflammation and microalbuminuria in hypertension. Arterioscler. Thromb. Vasc. Biol. 24, 2414-2419
25. Pedrinelli, R., Giampietro, O., Carmassi, F. et al. (1994) Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 344, 14-18
26. Taddei, S. and Salvetti, A. (2002) Endothelial dysfunction in essential hypertension: clinical implications. J. Hypertens. 20, 1671-1674
27. Goonasekera, C. D., Shah, V., Rees, D. D. and Dillon, M. J. (2000) Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma? Blood Press. 9, 16-21
28. Garg, J. P. and Bakris, G. L. (2002) Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc. Med. 7, 35-43
29. Jensen, J. S., Feldt-Rasmussen, B., Strandgaard, S., Schroll, M. and Borch-Johnsen, K. (2000) Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 35, 898-903
30. Jager, A., Kostense, P. J., Ruhe, H. G. et al. (1999) Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler. Thromb. Vasc. Biol. 19, 617-624
31. (1999) World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J. Hypertens. 17, 151-183
32. Ledue, T. B., Weiner, D. L., Sipe, J. D., Poulin, S. E., Collins, M. F. and Rifai, N. (1998) Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann. Clin. Biochem. 35, 745-753
33. Schulze, F., Wesemann, R., Schwedhelm, E. et al. (2004) Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin. Chem. Lab. Med. 42, 1377-1383
34. Thom, J., Gilmore, G., Yi, Q., Hankey, G. J. and Eikelboom, J. W. (2004) Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J. Thromb. Haemostasis 2, 2067-2069
35. Blann, A. D., Nadar, S. K. and Lip, G. Y. (2003) The adhesion molecule P-selectin and cardiovascular disease. Eur. Heart J. 24, 2166-2179
36. Davi, G., Romano, M., Mezzetti, A. et al. (1998) Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation. 97, 953-957
37. Andre, P. (2004) P-selectin in haemostasis. Br. J. Haematol. 126, 298-306
38. Tsioufis, C., Dimitriadis, K., Taxiarchou, E. et al. (2006) Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD40 ligand in male essential hypertensive subjects. Am. J. Hypertens. 19, 462-466
39. Bautista, L. E. (2006) Associations of microalbuminuria with inflammation markers in hypertensive men. Am. J. Hypertens. 19, 467
40. Desideri, G., Cipollone, F., Valeri, L. et al. (2007) Enhanced plasma soluble CD40 ligand levels in essential hypertensive patients with blunted nocturnal blood pressure decrease. Am. J. Hypertens. 20, 70-76
41. Patel, J. V., Lim, H. S., Nadar, S., Tayebjee, M., Hughes, E. A. and Lip, G. Y. (2006) Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J. Hypertens. 24, 117-121
42. Lee, W. L., Lee, W. J., Chen, Y. T. et al. (2006) The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease. Metab., Clin. Exp. 55, 1029-1034
43. Angelico, F., Alessandri, C., Ferro, D. et al. (2006) Enhanced soluble CD40L in patients with the metabolic syndrome: relationship with in vivo thrombin generation. Diabetologia 49, 1169-1174